Epidermal growth factor fusion toxin

Drug Profile

Epidermal growth factor fusion toxin

Alternative Names: DAB389-EGF; EGF diphtheria toxin chimeric protein

Latest Information Update: 18 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seragen
  • Developer Eli Lilly; Seragen
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Non-small cell lung cancer; Psoriasis; Solid tumours

Most Recent Events

  • 18 Sep 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 13 Jun 2003 Preclinical trials in Solid tumours in USA (unspecified route)
  • 07 Feb 2001 Discontinued-II for Non-small cell lung cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top